Press releases

23 May 2024

UCB announces publication in The Lancet of phase 3 bimekizumab▼ trials in moderate to severe hidradenitis suppurativa

17 May 2024

Transparency notification Wellington

17 May 2024

Acquisition of own shares

14 May 2024

New data published in the Journal of Neurology show clinically meaningful improvement of fatigue in generalized myasthenia gravis (gMG) with ZILBRYSQ[®]▼ (zilucoplan)

10 May 2024

Acquisition of own shares

8 May 2024

UCB presents final open-label extension FINTEPLA®▼(fenfluramine)[1] data at International Child Neurology Congress (ICNC) Annual Meeting

Press releases

Press releases

Search Press releases

UCB announces publication in The Lancet of phase 3 bimekizumab▼ trials in moderate to severe hidradenitis suppurativa

Transparency notification Wellington

Acquisition of own shares

New data published in the Journal of Neurology show clinically meaningful improvement of fatigue in generalized myasthenia gravis (gMG) with ZILBRYSQ[®]▼ (zilucoplan)

Acquisition of own shares

UCB presents final open-label extension FINTEPLA®▼(fenfluramine)[1] data at International Child Neurology Congress (ICNC) Annual Meeting

Choose a Country

UCB and Ailux Biologics Join Forces to Transform Biologics Research

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

Hidradenitis Suppurativa – Learn more about Hidradenitis Suppurativa an inflammatory skin disease

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

BIMZELX[®]▼(bimekizumab) two-year data at EHSF 2025 demonstrate sustained disease control in...

RYSTIGGO[®]▼(rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two...

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

UCB completes sale of established brands and updates 2024 financial guidance

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

UCB announces publication in The Lancet of phase 3 bimekizumab▼ trials in moderate to severe hidradenitis suppurativa

Transparency notification Wellington

Acquisition of own shares

New data published in the Journal of Neurology show clinically meaningful improvement of fatigue in generalized myasthenia gravis (gMG) with ZILBRYSQ[®]▼ (zilucoplan)

Acquisition of own shares

UCB presents final open-label extension FINTEPLA®▼(fenfluramine)[1] data at International Child Neurology Congress (ICNC) Annual Meeting

Choose a Country